New study checks safety of common painkiller in chest surgery nerve block

NCT ID NCT04807504

Completed Knowledge-focused Sponsor: Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at how the body processes ropivacaine, a numbing medicine, when given as a nerve block for chest surgery. Twenty adults having robotic or video-assisted chest surgery received the block, and researchers measured drug levels in their blood to check for toxicity. The goal was to better understand the safety of this newer nerve block technique.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ropivacaine (Naropin)
What this could lead to: If successful, this study could help doctors use ropivacaine more safely for nerve blocks in chest surgery, reducing the risk of serious side effects.
What could go wrong: This is a small, early-stage safety study with only 20 participants. It is not designed to prove the block works better than others, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCAL ANESTHETIC SYSTEMIC TOXICITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

local anesthetic poisoning Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCAL ANESTHETIC SYSTEMIC TOXICITY PAIN QUALITY OF RECOVERY

Contacts and locations

Locations

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.